Sunder Mudaliar
Overview
Explore the profile of Sunder Mudaliar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
3283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Green J, Everett B, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, et al.
Circulation
. 2024 Feb;
149(13):993-1003.
PMID: 38344820
Background: Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2...
2.
Alshaheri Durazo A, Weigand A, Bangen K, Membreno R, Mudaliar S, Thomas K
J Alzheimers Dis
. 2023 Dec;
97(1):219-228.
PMID: 38160359
Background: Type 2 diabetes mellitus (T2DM) affects ∼25% of Veterans, a prevalence rate double that of the general population. T2DM is associated with greater dementia risk and has been shown...
3.
Verma S, Mudaliar S, Greasley P
Adv Ther
. 2023 Nov;
41(1):92-112.
PMID: 37943443
There is a bidirectional pathophysiological interaction between the heart and the kidneys, and prolonged physiological stress to the heart and/or the kidneys can cause adverse cardiorenal complications, including but not...
4.
Wexler D, de Boer I, Ghosh A, Younes N, Bebu I, Inzucchi S, et al.
JAMA Intern Med
. 2023 May;
183(7):705-714.
PMID: 37213109
Importance: Type 2 diabetes (T2D) is the leading cause of kidney disease in the US. It is not known whether glucose-lowering medications differentially affect kidney function. Objective: To evaluate kidney...
5.
Mudaliar S
J Indian Inst Sci
. 2023 Feb;
:1-11.
PMID: 36845885
Diabetes is an ancient disease and for centuries extreme diets and herbal remedies were used to treat diabetes symptoms. The discovery of insulin in 1921 transformed the landscape of diabetes...
6.
Ekanayake P, Mudaliar S
Diabetes Metab Syndr
. 2023 Jan;
17(2):102702.
PMID: 36657305
Background And Aims: The SGLT2-inhibitors significantly reduce heart failure hospitalization and progression to end-stage kidney disease. An increase in hemoglobin/hematocrit is seen with SGLT2i-inhibitor treatment. This increase has been attributed...
7.
Ekanayake P, Mudaliar S
Indian J Med Res
. 2022 May;
154(5):655-657.
PMID: 35532581
No abstract available.
8.
Khunti K, Jabbour S, Cos X, Mudaliar S, Mende C, Bonaca M, et al.
Diabetes Obes Metab
. 2022 Mar;
24(7):1187-1196.
PMID: 35238129
Recent advances in type 2 diabetes (T2D) research have highlighted the benefits of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, including cardiovascular and renal protection. However, uptake rates of these drugs remain low...
9.
Ekanayake P, Mudaliar S
Diabetes Obes Metab
. 2021 Oct;
24(1):3-11.
PMID: 34605129
The cardio-renal benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors are well established. In 2016, we postulated that these benefits are attributable, in part, to the occurrence of chronic low-grade ketonaemia and...
10.
Mudaliar S, Hupfeld C, Chao D
J Clin Endocrinol Metab
. 2021 Jan;
106(5):1235-1244.
PMID: 33512450
Diabetic retinopathy (DR) is a well-recognized microvascular complication of diabetes. Growing evidence suggests that, in addition to retinal vascular damage, there is significant damage to retinal neural tissue in DR....